BACKGROUND:Cocaine dependence is a substantial public health problem, yet there are no clearly effective medication treatments. Amphetamine and topiramate have both shown promise for the treatment of cocaine dependence in preclinical and early-stage clinical studies. METHODS:Eighty-one cocaine-dependent adults were randomized to receive a combination of extended-release mixed amphetamine salts (MAS-ER) and topiramate or placebo for 12 weeks under double-blind conditions. MAS-ER doses were titrated over 2 weeks to a maximum dose of 60 mg daily, and topiramate doses were titrated over 6 weeks to a maximum dose of 150 mg twice daily. All participants received a supportive behavioral intervention. The primary outcome was the proportion of individuals who achieved 3 consecutive weeks of abstinence as measured by urine toxicology confirmed self-report. RESULTS: The overall proportion of participants who achieved 3 consecutive weeks of abstinence was larger in the extended-release mixed amphetamine salts and topiramate group (33.3%) than in placebo group (16.7%). There was a significant moderating effect of baseline total number of cocaine use days (Wald χ(2) = 3.75, df = 1, p = .05) on outcome, suggesting that the combination treatment was most effective for participants with a high baseline frequency of cocaine use. CONCLUSIONS: The results of this study supported our hypothesis that the combination of MAS-ER and topiramate would be superior to placebo in achieving 3 weeks of consecutive abstinence. These findings provide evidence that the combination of MAS-ER and topiramate is efficacious in promoting abstinence in cocaine-dependent individuals.
RCT Entities:
BACKGROUND:Cocaine dependence is a substantial public health problem, yet there are no clearly effective medication treatments. Amphetamine and topiramate have both shown promise for the treatment of cocaine dependence in preclinical and early-stage clinical studies. METHODS: Eighty-one cocaine-dependent adults were randomized to receive a combination of extended-release mixed amphetamine salts (MAS-ER) and topiramate or placebo for 12 weeks under double-blind conditions. MAS-ER doses were titrated over 2 weeks to a maximum dose of 60 mg daily, and topiramate doses were titrated over 6 weeks to a maximum dose of 150 mg twice daily. All participants received a supportive behavioral intervention. The primary outcome was the proportion of individuals who achieved 3 consecutive weeks of abstinence as measured by urine toxicology confirmed self-report. RESULTS: The overall proportion of participants who achieved 3 consecutive weeks of abstinence was larger in the extended-release mixed amphetamine salts and topiramate group (33.3%) than in placebo group (16.7%). There was a significant moderating effect of baseline total number of cocaine use days (Wald χ(2) = 3.75, df = 1, p = .05) on outcome, suggesting that the combination treatment was most effective for participants with a high baseline frequency of cocaine use. CONCLUSIONS: The results of this study supported our hypothesis that the combination of MAS-ER and topiramate would be superior to placebo in achieving 3 weeks of consecutive abstinence. These findings provide evidence that the combination of MAS-ER and topiramate is efficacious in promoting abstinence in cocaine-dependent individuals.
Authors: Bankole A Johnson; Robert M Swift; Giovanni Addolorato; Domenic A Ciraulo; Hugh Myrick Journal: Alcohol Clin Exp Res Date: 2005-02 Impact factor: 3.455
Authors: Deborah B Leiderman; Steve Shoptaw; Ann Montgomery; Daniel A Bloch; Ahmed Elkashef; Joseph LoCastro; Frank Vocci Journal: Addiction Date: 2005-03 Impact factor: 6.526
Authors: Mehmet Sofuoglu; Susan Dudish-Poulsen; James Poling; Marc Mooney; Dorothy K Hatsukami Journal: Addict Behav Date: 2004-11-02 Impact factor: 3.913
Authors: Adam Bisaga; Efrat Aharonovich; Fatima Garawi; Frances R Levin; Eric Rubin; Wilfrid N Raby; Suzanne K Vosburg; Edward V Nunes Journal: Drug Alcohol Depend Date: 2005-01-07 Impact factor: 4.492
Authors: Charles A Dackis; Kyle M Kampman; Kevin G Lynch; Helen M Pettinati; Charles P O'Brien Journal: Neuropsychopharmacology Date: 2005-01 Impact factor: 7.853
Authors: Bankole A Johnson; Robert M Swift; Nassima Ait-Daoud; Carlo C DiClemente; Martin A Javors; Robert J Malcolm Journal: Alcohol Clin Exp Res Date: 2004-02 Impact factor: 3.455
Authors: Kyle M Kampman; Helen Pettinati; Kevin G Lynch; Charles Dackis; Thorne Sparkman; Catherine Weigley; Charles P O'Brien Journal: Drug Alcohol Depend Date: 2004-09-06 Impact factor: 4.492
Authors: Mark A Smith; Michael M Pennock; Elizabeth G Pitts; Katherine L Walker; Kimberly C Lang Journal: Behav Brain Res Date: 2014-08-12 Impact factor: 3.332
Authors: Lianping Ti; Lindsey Richardson; Kora DeBeck; Paul Nguyen; Julio Montaner; Evan Wood; Thomas Kerr Journal: Drug Alcohol Depend Date: 2014-05-17 Impact factor: 4.492
Authors: Gillinder Bedi; Laura Shiffrin; Nehal P Vadhan; Edward V Nunes; Richard W Foltin; Adam Bisaga Journal: J Psychopharmacol Date: 2016-02-26 Impact factor: 4.153